TIMP2 and ovarian cancer: On the other hand, a recent study has reported that increased TIMP-2 expression in the stromal compartment, but not in tumor cells, is associated with an enhanced response to cisplatin and paclitaxel-based chemotherapy in ovarian cancer patients [189].